Deutsche Bank AG Invests $3.70 Million in Harmony Biosciences Holdings, Inc. $HRMY

Deutsche Bank AG acquired a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 101,612 shares of the company’s stock, valued at approximately $3,700,000.

Other institutional investors have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its position in shares of Harmony Biosciences by 589.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock worth $28,000 after purchasing an additional 643 shares during the last quarter. Allworth Financial LP increased its holdings in Harmony Biosciences by 286.7% in the fourth quarter. Allworth Financial LP now owns 812 shares of the company’s stock valued at $30,000 after purchasing an additional 602 shares during the last quarter. Leonteq Securities AG acquired a new position in Harmony Biosciences in the fourth quarter valued at about $30,000. National Bank of Canada FI bought a new position in Harmony Biosciences during the third quarter worth about $40,000. Finally, Clearstead Advisors LLC increased its stake in shares of Harmony Biosciences by 145.9% in the 4th quarter. Clearstead Advisors LLC now owns 1,178 shares of the company’s stock valued at $44,000 after acquiring an additional 699 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. Oppenheimer reissued an “outperform” rating and set a $70.00 price target on shares of Harmony Biosciences in a research report on Tuesday, August 4th. UBS Group restated a “neutral” rating and issued a $37.00 price target on shares of Harmony Biosciences in a report on Wednesday, August 5th. Zacks Research cut Harmony Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. HC Wainwright reissued a “buy” rating and set a $55.00 target price on shares of Harmony Biosciences in a research note on Thursday, July 16th. Finally, Weiss Ratings raised shares of Harmony Biosciences from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, August 17th. Four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $45.50.

Harmony Biosciences Stock Up 1.2%

Harmony Biosciences stock opened at $38.95 on Wednesday. The company has a fifty day simple moving average of $36.51 and a 200 day simple moving average of $32.74. The company has a current ratio of 3.48, a quick ratio of 3.45 and a debt-to-equity ratio of 0.13. Harmony Biosciences Holdings, Inc. has a 1-year low of $25.52 and a 1-year high of $40.87. The company has a market cap of $2.27 billion, a P/E ratio of 12.65, a price-to-earnings-growth ratio of 0.36 and a beta of 0.96.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $1.28 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.32. Harmony Biosciences had a return on equity of 20.06% and a net margin of 18.88%.The company had revenue of $261.28 million during the quarter, compared to analysts’ expectations of $250.77 million. During the same quarter last year, the company earned $0.92 EPS. Harmony Biosciences’s revenue for the quarter was up 30.3% compared to the same quarter last year. Research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 3.77 earnings per share for the current fiscal year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.